Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.44, $0.27 worse than the analyst estimate of $1.71. Revenue for the quarter came in at $5.8 billion versus the consensus estimate of $5.49 billion.

GUIDANCE:

Gilead Sciences sees FY2019 revenue of $21.3-21.8 billion, versus the consensus of $21.74 billion.

• Product Gross Margin 85% - 87%

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

Earnings Guidance Hot Earnings Hot Guidance

Gilead Sciences (GILD) PT Lowered to $90 at Raymond JamesFebruary 5, 2019 9:00 AM Gilead Sciences (GILD) PT Lowered to $100 at CitiFebruary 5, 2019 6:59 AM Gilead Sciences (GILD) PT Raised to $89 at RBC CapitalFebruary 5, 2019 6:46 AM Gilead Sciences (GILD) Raises Quarterly Dividend 10.5% to $0.63; 3.6% YieldFebruary 4, 2019 4:03 PM Gilead Sciences Announces 11 Percent Increase in First Quarter 2019 DividendFebruary 4, 2019 4:02 PM